Show simple item record

dc.contributor.authorWalter, F
dc.contributor.authorThompson, MJ
dc.contributor.authorWellwood, I
dc.contributor.authorAbel, G
dc.contributor.authorHamilton, W
dc.contributor.authorJohnson, M
dc.contributor.authorLyratzopoulos, G
dc.contributor.authorMessenger, M
dc.contributor.authorNeal, R
dc.contributor.authorGreg, R
dc.contributor.authorHardeep, S
dc.contributor.authorSpencer, AE
dc.contributor.authorSutton, S
dc.contributor.authorVedsted, P
dc.contributor.authorEmery, J
dc.date.accessioned2019-05-23T14:38:36Z
dc.date.issued2019-06-14
dc.description.abstractBackground Novel diagnostic triage and testing strategies to support early detection of cancer could improve clinical outcomes. Most apparently promising diagnostic tests ultimately fail because of inadequate performance in real‐world, low prevalence populations such as primary care or general community populations. They should therefore be systematically evaluated before implementation to determine whether they lead to earlier detection, are cost‐effective, and improve patient safety and quality of care, while minimising over‐ investigation and over‐diagnosis. Methods We performed a systematic scoping review of frameworks for the evaluation of tests and diagnostic approaches. Results We identified 16 frameworks: none addressed the entire continuum from test development to impact on diagnosis and patient outcomes in the intended population, nor the way in which tests may be used for triage purposes as part of a wider diagnostic strategy. Informed by these findings, we developed a new framework, the ‘CanTest Framework’, which proposes five iterative research phases forming a clear translational pathway from new test development to health system implementation and evaluation. Conclusion This framework is suitable for testing in low prevalence populations, where tests are often applied for triage testing and incorporated into a wider diagnostic strategy. It has relevance for a wide range of stakeholders including patients, policymakers, purchasers, healthcare providers and industry.en_GB
dc.description.sponsorshipCancer Research UKen_GB
dc.description.sponsorshipNHMRCen_GB
dc.description.sponsorshipNational Institute for Health Research (NIHR)en_GB
dc.description.sponsorshipHouston VA HSR&D Center for Innovations in Quality, Effectiveness and Safetyen_GB
dc.description.sponsorshipAgency for Health Care Research and Qualityen_GB
dc.description.sponsorshipa PCORI methods research award (Patient Centered Research on Outcomes of Diagnostic Testingen_GB
dc.identifier.citationVol. 19 (586). Published online 14 June 2019.en_GB
dc.identifier.doihttps://doi.org/10.1186/s12885-019-5746-6
dc.identifier.grantnumberC8640/A23385en_GB
dc.identifier.grantnumberC18081/A18180en_GB
dc.identifier.grantnumberPractitioner Fellowshipen_GB
dc.identifier.grantnumberCIN 13‐413en_GB
dc.identifier.grantnumberR01HS022087en_GB
dc.identifier.grantnumberME‐1503‐29245en_GB
dc.identifier.urihttp://hdl.handle.net/10871/37208
dc.language.isoenen_GB
dc.publisherBioMed Centralen_GB
dc.rights© The Author(s), 2019. Open Access. This article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
dc.subjectCanceren_GB
dc.subjectdiagnostic strategiesen_GB
dc.subjectearly detectionen_GB
dc.subjectdiagnosisen_GB
dc.subjectconceptual frameworken_GB
dc.subjectprimary careen_GB
dc.titleEvaluating diagnostic strategies for early detection of cancer: the CanTest Frameworken_GB
dc.typeArticleen_GB
dc.date.available2019-05-23T14:38:36Z
dc.identifier.issn1471-2407
dc.descriptionThis is the author accepted manuscript. The final version is available from BioMed Central via the DOI in this record.en_GB
dc.identifier.journalBMC Canceren_GB
dc.rights.urihttp://www.rioxx.net/licenses/all-rights-reserveden_GB
dcterms.dateAccepted2019-03-01
rioxxterms.versionAMen_GB
rioxxterms.licenseref.startdate2019-03-01
rioxxterms.typeJournal Article/Reviewen_GB
refterms.dateFCD2019-05-23T14:30:40Z
refterms.versionFCDAM
refterms.dateFOA2019-06-20T13:38:47Z
refterms.panelAen_GB


Files in this item

This item appears in the following Collection(s)

Show simple item record